DBV Tech Advances BLA Submission for VIASKIN Peanut Patch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy DBVT?
Source: Newsfilter
- Application Progress: DBV Tech is advancing its Biologics License Application (BLA) for the VIASKIN peanut patch, marking a significant milestone in the treatment of allergies in children, which is expected to enhance its market competitiveness.
- Analyst Rating: Analysts maintain a 'Buy' rating on DBV Tech with a target price of $51, reflecting positive market expectations regarding the product's potential, which may attract more investor interest.
- Market Outlook: The VIASKIN peanut patch represents an innovative therapy aimed at providing safe and effective allergy treatment for children, and if approved, it will help the company secure a position in the rapidly growing allergy treatment market.
- Strategic Implications: By advancing the BLA submission, DBV Tech not only demonstrates its R&D capabilities but also potentially lays the groundwork for future product line expansions, thereby enhancing overall business growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DBVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DBVT
Wall Street analysts forecast DBVT stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.000
Low
40.00
Averages
46.40
High
51.00
Current: 20.000
Low
40.00
Averages
46.40
High
51.00
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DBV Tech Advances BLA Submission for VIASKIN Peanut Patch
- Application Progress: DBV Tech is advancing its Biologics License Application (BLA) for the VIASKIN peanut patch, marking a significant milestone in the treatment of allergies in children, which is expected to enhance its market competitiveness.
- Analyst Rating: Analysts maintain a 'Buy' rating on DBV Tech with a target price of $51, reflecting positive market expectations regarding the product's potential, which may attract more investor interest.
- Market Outlook: The VIASKIN peanut patch represents an innovative therapy aimed at providing safe and effective allergy treatment for children, and if approved, it will help the company secure a position in the rapidly growing allergy treatment market.
- Strategic Implications: By advancing the BLA submission, DBV Tech not only demonstrates its R&D capabilities but also potentially lays the groundwork for future product line expansions, thereby enhancing overall business growth potential.
See More
DBV Technologies Releases FY 2025 Financial Results
- Financial Performance: DBV Technologies reported a GAAP EPS of -$1.05 for FY 2025, indicating ongoing challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, DBV held $194.2 million in cash and cash equivalents, a significant increase from $32.5 million in 2024, reflecting improved cash management practices.
- Operating Cash Usage: The net cash used for operating activities was $121.2 million in 2025 compared to $104.5 million in 2024, highlighting that despite increased cash reserves, high operational expenditures remain a significant financial pressure for the company.
- Industry Engagement: DBV Technologies is set to present at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting, indicating active participation in the industry that may pave the way for future collaborations and funding opportunities.
See More
DBV Technologies Files 2025 Annual Report and URD
- Annual Report Filing: On March 26, 2026, DBV Technologies filed its 2025 Annual Report on Form 10-K with the SEC and its Universal Registration Document (URD) with the AMF, ensuring compliance and enhancing transparency for investors.
- Compliance Disclosure: The 2025 URD includes the annual financial report, corporate governance report, share buy-back program description, and statutory auditor reports, fulfilling the requirements of Article L. 225-37 of the French Commercial Code, thereby boosting investor confidence.
- Focus on Allergy Treatment: DBV Technologies is dedicated to developing treatment options for food allergies, particularly through its proprietary VIASKIN® patch technology, which aims to introduce microgram amounts of biologically active compounds through the skin to retrain the immune system, addressing significant unmet medical needs in the market.
- Clinical Trial Progress: The company is currently conducting clinical trials of the VIASKIN® Peanut Patch for food-allergic toddlers and children aged 1 to 7, demonstrating potential in alleviating allergy symptoms and further solidifying DBV Technologies' market position in the biopharmaceutical sector.
See More
Total Voting Rights and Shares as of February 28, 2026
- Total Shares: As of February 28, 2026, the company has a total of 278,352,082 shares, reflecting the company's stability in the market and transparency in shareholder structure, which ensures investor confidence in corporate governance.
- Total Voting Rights: The total voting rights on the same date amount to 278,352,082, indicating the distribution of voting rights at shareholder meetings, which facilitates shareholder participation in corporate decision-making processes.
- Net Voting Rights: The net voting rights stand at 278,236,200, suggesting that a certain proportion of shares lack voting rights, which may impact shareholders' influence and voice in significant decisions.
- Compliance Information: The disclosure of voting rights and share information is in accordance with Article 223-16 of the French Financial Markets Authority, enhancing market transparency and compliance, thus meeting regulatory requirements.
See More
DBV Technologies' VIASKIN Peanut Patch Achieves Phase 3 Trial Success
- Clinical Trial Success: DBV Technologies' VIASKIN peanut patch met its primary endpoint in the pivotal Phase 3 VITESSE trial, demonstrating significant desensitization in children aged 4 to 7, addressing the urgent need for safe and effective therapies.
- Efficacy Data: 46.6% of children in the treatment group were responders at 12 months compared to only 14.8% in the placebo group, indicating a significant advantage in increasing children's tolerance thresholds.
- Good Safety Profile: The therapy was generally well tolerated, with most adverse events limited to mild localized skin reactions, demonstrating its safety and acceptability in clinical applications.
- Future Plans: DBV Technologies plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2026, and if approved, the VIASKIN peanut patch could become the first non-invasive, patch-based therapy for peanut allergy, presenting significant market potential.
See More
DBV Technologies Presents Positive Data from VIASKIN® Peanut Patch Study
- Clinical Trial Success: At the AAAAI 2026 Annual Meeting, DBV Technologies presented data from the Phase 3 VITESSE study of the VIASKIN® Peanut Patch, showing that 83% of children increased their eliciting dose at 12 months compared to 48% in the placebo group, indicating significant efficacy of this treatment in peanut-allergic children.
- Significant Treatment Effect: Among the treated group, 46.6% of children met the treatment responder criteria at 12 months, compared to only 14.8% in the placebo group, with a difference of 31.8%, exceeding the pre-specified threshold of 15%, thus laying a solid foundation for future FDA applications.
- Good Safety Profile: The VIASKIN® Peanut Patch was well tolerated, with the majority of treatment-emergent adverse events being mild local reactions, consistent with DBV's previous Phase 3 studies, demonstrating the product's safety in clinical applications.
- Huge Market Potential: If approved, the VIASKIN® Peanut Patch would provide a non-invasive treatment option for peanut-allergic children that fits into daily activities, with DBV planning to submit a Biologics License Application to the FDA in the first half of this year, further advancing its market entry.
See More
DBV Tech Advances BLA Submission for VIASKIN Peanut Patch
- Application Progress: DBV Tech is advancing its Biologics License Application (BLA) for the VIASKIN peanut patch, marking a significant milestone in the treatment of allergies in children, which is expected to enhance its market competitiveness.
- Analyst Rating: Analysts maintain a 'Buy' rating on DBV Tech with a target price of $51, reflecting positive market expectations regarding the product's potential, which may attract more investor interest.
- Market Outlook: The VIASKIN peanut patch represents an innovative therapy aimed at providing safe and effective allergy treatment for children, and if approved, it will help the company secure a position in the rapidly growing allergy treatment market.
- Strategic Implications: By advancing the BLA submission, DBV Tech not only demonstrates its R&D capabilities but also potentially lays the groundwork for future product line expansions, thereby enhancing overall business growth potential.
See More
DBV Technologies Releases FY 2025 Financial Results
- Financial Performance: DBV Technologies reported a GAAP EPS of -$1.05 for FY 2025, indicating ongoing challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, DBV held $194.2 million in cash and cash equivalents, a significant increase from $32.5 million in 2024, reflecting improved cash management practices.
- Operating Cash Usage: The net cash used for operating activities was $121.2 million in 2025 compared to $104.5 million in 2024, highlighting that despite increased cash reserves, high operational expenditures remain a significant financial pressure for the company.
- Industry Engagement: DBV Technologies is set to present at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting, indicating active participation in the industry that may pave the way for future collaborations and funding opportunities.
See More
DBV Technologies Files 2025 Annual Report and URD
- Annual Report Filing: On March 26, 2026, DBV Technologies filed its 2025 Annual Report on Form 10-K with the SEC and its Universal Registration Document (URD) with the AMF, ensuring compliance and enhancing transparency for investors.
- Compliance Disclosure: The 2025 URD includes the annual financial report, corporate governance report, share buy-back program description, and statutory auditor reports, fulfilling the requirements of Article L. 225-37 of the French Commercial Code, thereby boosting investor confidence.
- Focus on Allergy Treatment: DBV Technologies is dedicated to developing treatment options for food allergies, particularly through its proprietary VIASKIN® patch technology, which aims to introduce microgram amounts of biologically active compounds through the skin to retrain the immune system, addressing significant unmet medical needs in the market.
- Clinical Trial Progress: The company is currently conducting clinical trials of the VIASKIN® Peanut Patch for food-allergic toddlers and children aged 1 to 7, demonstrating potential in alleviating allergy symptoms and further solidifying DBV Technologies' market position in the biopharmaceutical sector.
See More
Total Voting Rights and Shares as of February 28, 2026
- Total Shares: As of February 28, 2026, the company has a total of 278,352,082 shares, reflecting the company's stability in the market and transparency in shareholder structure, which ensures investor confidence in corporate governance.
- Total Voting Rights: The total voting rights on the same date amount to 278,352,082, indicating the distribution of voting rights at shareholder meetings, which facilitates shareholder participation in corporate decision-making processes.
- Net Voting Rights: The net voting rights stand at 278,236,200, suggesting that a certain proportion of shares lack voting rights, which may impact shareholders' influence and voice in significant decisions.
- Compliance Information: The disclosure of voting rights and share information is in accordance with Article 223-16 of the French Financial Markets Authority, enhancing market transparency and compliance, thus meeting regulatory requirements.
See More
DBV Technologies' VIASKIN Peanut Patch Achieves Phase 3 Trial Success
- Clinical Trial Success: DBV Technologies' VIASKIN peanut patch met its primary endpoint in the pivotal Phase 3 VITESSE trial, demonstrating significant desensitization in children aged 4 to 7, addressing the urgent need for safe and effective therapies.
- Efficacy Data: 46.6% of children in the treatment group were responders at 12 months compared to only 14.8% in the placebo group, indicating a significant advantage in increasing children's tolerance thresholds.
- Good Safety Profile: The therapy was generally well tolerated, with most adverse events limited to mild localized skin reactions, demonstrating its safety and acceptability in clinical applications.
- Future Plans: DBV Technologies plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2026, and if approved, the VIASKIN peanut patch could become the first non-invasive, patch-based therapy for peanut allergy, presenting significant market potential.
See More
DBV Technologies Presents Positive Data from VIASKIN® Peanut Patch Study
- Clinical Trial Success: At the AAAAI 2026 Annual Meeting, DBV Technologies presented data from the Phase 3 VITESSE study of the VIASKIN® Peanut Patch, showing that 83% of children increased their eliciting dose at 12 months compared to 48% in the placebo group, indicating significant efficacy of this treatment in peanut-allergic children.
- Significant Treatment Effect: Among the treated group, 46.6% of children met the treatment responder criteria at 12 months, compared to only 14.8% in the placebo group, with a difference of 31.8%, exceeding the pre-specified threshold of 15%, thus laying a solid foundation for future FDA applications.
- Good Safety Profile: The VIASKIN® Peanut Patch was well tolerated, with the majority of treatment-emergent adverse events being mild local reactions, consistent with DBV's previous Phase 3 studies, demonstrating the product's safety in clinical applications.
- Huge Market Potential: If approved, the VIASKIN® Peanut Patch would provide a non-invasive treatment option for peanut-allergic children that fits into daily activities, with DBV planning to submit a Biologics License Application to the FDA in the first half of this year, further advancing its market entry.
See More
